The results underscore MCS-8’s previously indicated multifaceted clinical and commercial potential beyond its clinical evidence in prostate cancer prevention, showing its potential in helping alleviate high-grade malignancy risk.
This year, EPC Groupe participated in FMF26, supporting our joint venture in the KingdomMCS, developed with our partner MCC... Our partner MCS. Discover MCS.